Pliant Therapeutics, Inc. (PLRX) Monday announced the discontinuation of its BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis following recommendations from an independent Data Safety Monitoring Board and an external expert panel.
The decision was driven by an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups, although early signs of efficacy on lung function were observed.
Pliant plans to analyze the full trial data to determine next steps, including potential lower-dose studies. The company remains focused on advancing other programs, including its PLN-101095 oncology trial, with interim data expected in early 2025.
PLRX is currently trading at $1.75, down 49.27 percent or $1.69 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.